rhTPO dosing for chemotherapy-induced thrombocytopenia in hepatocellular carcinoma patients undergoing interventional therapy

Phase 4, open-label trial of recombinant human thrombopoietin in hepatocellular carcinoma (HCC) and chemotherapy-induced thrombocytopenia (CIT) (3 arms), sponsored by Tianjin Third Central Hospital. Primary endpoint: Proportion of subjects with platelet count ≥ 50 × 10^9/L on postoperative day 5 without emergency treatment for bleeding. Planned start Aug 2026; status: not yet recruiting.